BCL2L1

Across TCGA pan-cancer cohorts, BCL2L1 RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of BCL2L1’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where BCL2L1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types BCL2L1 is over-expressed in tumor, although a few such as LUSC show the opposite, repressed pattern.

COAD, THCA, and STAD are the cancer types where BCL2L1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BCL2L1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Male	II,III,IV	+1.245	<.001	11	view →
THCA	Male	III,IV	+1.241	<.001	11	view →
STAD	All	II,III,IV	+1.371	<.001	9	view →
LIHC	Male	II,III,IV	+1.196	<.001	9	view →
KIRP	All	II,III,IV	+0.883	<.001	9	view →
BRCA	All	III,IV	+0.805	<.001	6	view →
HNSC	All	All	+0.459	<.001	6	view →
KIRC	All	All	+0.247	<.001	6	view →
READ	All	All	+1.038	<.001	5	view →
LUSC	Female	All	−0.550	.007	4	view →
BLCA	All	All	+0.533	.018	4	view →
CHOL	All	All	+2.760	<.001	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 15 lineages.

BCL2L1–COAD

Open the COAD breakdown →